Table 5. Demographic and clinical characteristics of DENV-3 cases, Hospital Study, 2005–11.
| 2005–9 | 2009–10 | 2010–11 | p-value3 | |
| Symptomatic dengue cases, serotype 3 | 112 | 175 | 104 | |
| Sex | 0.861 | |||
| Female | 58 (51.8) | 87 (49.7) | 50 (48.1) | |
| Male | 54 (48.2) | 88 (50.3) | 88 (50.3) | |
| Age, years (median, IQR) | 7.0 (3.4–9.3) | 8.6 (5.2–10.7) | 8.5 (5.8–11.6) | 0.003 |
| Immune Response 1 | 0.805 | |||
| Primary | 61 (56.0) | 88 (52.4) | 55 (55.6) | |
| Secondary | 48 (44.0) | 80 (47.6) | 44 (44.4) | |
| Day of presentation after onset of symptoms (median, IQR) | 5 (4–5) | 3 (2–4) | 4 (3–4) | <0.001 |
| Care | ||||
| Out-patient | 27 (24.1) | 22 (12.6) | 8 (7.7) | 0.002 |
| In-patient | 81 (72.3) | 120 (68.6) | 91 (87.5) | 0.002 |
| Intensive care | 4 (3.6) | 33 (18.8) | 5 (4.8) | <0.001 |
| Classification | ||||
| Dengue Fever (DF) | 69 (61.6) | 89 (50.9) | 63 (60.6) | 0.125 |
| Dengue Fever with Compensated Shock (DFCS) | 8 (7.1) | 37 (21.1) | 11 (10.6) | 0.002 |
| Dengue w/ Signs Associated w/Shock (DSAS) | 2 (1.8) | 24 (13.7) | 3 (2.9) | <0.001 |
| Dengue Hemorrhagic Fever (DHF) | 27 (24.1) | 20 (11.4) | 25 (24.0) | 0.006 |
| Dengue Shock Syndrome (DSS) | 6 (5.4) | 5 (2.9) | 2 (1.9) | 0.386 |
| Clinical Signs and Symptoms | ||||
| Hemorrhagic manifestations 2 | 90 (80.4) | 148 (84.6) | 83 (79.8) | 0.514 |
| Mucosal bleeding | 18 (16.1) | 32 (18.3) | 13 (12.5) | 0.446 |
| Positive tourniquet test | 49 (43.7) | 102 (58.3) | 42 (40.4) | 0.006 |
| Petechiae | 88 (78.6) | 136 (77.7) | 79 (76.0) | 0.896 |
| Rash | 107 (95.4) | 162 (92.6) | 101 (97.1) | 0.276 |
| Platelets ≤100,000/mm3 | 51 (45.5) | 46 (26.3) | 38 (36.5) | 0.003 |
| Leukopenia (WBC ≤5,000/mm3) | 86 (76.8) | 162 (92.6) | 94 (90.4) | <0.001 |
| Cold extremities | 32 (28.6) | 92 (52.6) | 39 (37.5) | <0.001 |
| Capillary refill >2 seconds | 19 (17.0) | 74 (42.3) | 24 (23.1) | <0.001 |
| Compensated shock | 18 (16.1) | 71 (40.6) | 24 (23.1) | <0.001 |
1
In the hospital study, immune response is known in 109, 168, and 99 DENV-3 cases in years 2008–9, 2009–10, and 2010–11, respectively.
2
Hemorrhagic manifestations do not include laboratory values and are defined as presence of any of the following clinical signs and symptoms: petechiae, rash, positive tourniquet test, bruising, hematoma, hemoptysis, epistaxis, gingivorrhagia, melena, hematemesis, hematuria, subconjunctival hemorrhage, vaginal hemorrhage, hypermenorrhea and excessive bleeding at puncture site.
3
p-values were calculated using the Chi-square tests, except for mean age and mean day of presentation, for which Mann-Whitney t-tests were applied.